{
    "clinical_study": {
        "@rank": "90568", 
        "arm_group": [
            {
                "arm_group_label": "Misoprostol", 
                "arm_group_type": "Experimental", 
                "description": "600 mcg oral misoprostol administered during the third stage of labor"
            }, 
            {
                "arm_group_label": "UnijectTM", 
                "arm_group_type": "Experimental", 
                "description": "10 IU oxytocin delivered IM with UnijectTM during he third stage of labor"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a large, community-based, cluster-randomized trial to compare routine prophylactic\n      use of 600 mcg oral misoprostol and 10 IU oxytocin delivered by UnijectTM intramuscularly\n      during the third stage of labor"
        }, 
        "brief_title": "Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Postpartum Hemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Postpartum Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will assess the programmatic implications (including feasibility, acceptability,\n      risks and benefits) at the community level of the introduction of misoprostol and/or\n      oxytocin in UnijectTM for the prevention of PPH and will help to identify the appropriate\n      niche for both drugs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  women delivering in community health centers (case de sante) with a trained study\n             provider (matrone) who are able to provide informed consent\n\n        Exclusion Criteria:\n\n          -  women with known contraindications to prostaglandins"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "682", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01713153", 
            "org_study_id": "2.4.9"
        }, 
        "intervention": [
            {
                "arm_group_label": "Misoprostol", 
                "description": "600 mcg misoprostol oral", 
                "intervention_name": "Misoprostol", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cytotec", 
                    "Misoclear"
                ]
            }, 
            {
                "arm_group_label": "UnijectTM", 
                "description": "10 IU oxytocin delivered intramuscularly with UnijectTM", 
                "intervention_name": "UnijectTM", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxytocin", 
                "Misoprostol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "postpartum hemorrhage", 
            "prevention", 
            "misoprostol", 
            "Uniject", 
            "oxytocin"
        ], 
        "lastchanged_date": "October 22, 2012", 
        "link": {
            "description": "Related Info", 
            "url": "http://gynuity.org/programs/more/prevention-of-postpartum-prevention"
        }, 
        "location": {
            "contact": {
                "email": "mdiagne@senegal.childfund.org", 
                "last_name": "Mamadou Diagne", 
                "phone": "+221776342918"
            }, 
            "contact_backup": {
                "email": "msow@senegal.childfund.org", 
                "last_name": "Maimouna Sow", 
                "phone": "+221776357924"
            }, 
            "facility": {
                "address": {
                    "city": "Thiadiay and Kolda", 
                    "country": "Senegal", 
                    "state": "Thiadiaye and Kolda"
                }, 
                "name": "Health huts in the district of Thiadiaye and Kolda"
            }, 
            "investigator": [
                {
                    "last_name": "Bocar Daff", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Mamadou Diagne", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ayisha Diop", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jennifer Blum", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Senegal"
        }, 
        "number_of_arms": "2", 
        "official_title": "Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin Uniject in Senegal", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Senegal: Ministry of Health and Prevention", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To establish the comparable effectiveness of two technologies, individual pre- and post-delivery Hb measures will be taken to calculate change in Hb. This will be done using a Hemocue Hemoglobin machine + cuvette (HemoCue, Angelholm, Sweden). The Hemocue is a simple means of collecting Hb measures at the community-level where traditional laboratory techniques are not feasible", 
            "measure": "Mean change in hemoglobin", 
            "safety_issue": "No", 
            "time_frame": "during 3rd trimester and 1-3 days postpartum"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01713153"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "nausea, vomiting, diarrhea, shivering, fever", 
                "measure": "Occurrence and management of side effects", 
                "safety_issue": "Yes", 
                "time_frame": "1 hour postpartum"
            }, 
            {
                "description": "administration of the drug after the birth of the baby and verifying no twin, before the expulsion of the placenta", 
                "measure": "correct timing of drug administration", 
                "safety_issue": "Yes", 
                "time_frame": "collected immediately following birth, verified 1-3 days postpartum"
            }, 
            {
                "measure": "change in hemoglobin \u2265 2 g/dL", 
                "safety_issue": "No", 
                "time_frame": "during third trimester and 1-3 days postpartum"
            }, 
            {
                "description": "use of additional uterotonics, manual removal of placental fragments, etc", 
                "measure": "additional interventions", 
                "safety_issue": "No", 
                "time_frame": "during birth"
            }, 
            {
                "description": "referral requested, transfers carried out, reasons for incomplete referrals/transfers", 
                "measure": "referrals", 
                "safety_issue": "No", 
                "time_frame": "0-3 days postpartum"
            }, 
            {
                "description": "acceptability according to woman of study medication, care received, side effects experienced", 
                "measure": "acceptability", 
                "safety_issue": "No", 
                "time_frame": "1-3 days postpartum"
            }
        ], 
        "source": "Gynuity Health Projects", 
        "sponsors": {
            "collaborator": {
                "agency": "Child Fund International", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Gynuity Health Projects", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}